3,4-Methylenedioxy analogues of amphetamine: Defining the risks to humans

被引：138

作者：

Hegadoren, KM ^{[1
]}

Baker, GB

Bourin, M

机构：

[1] Univ Alberta, Fac Nursing, Dept Psychiat, Edmonton, AB T6G 2G3, Canada

[2] Univ Alberta, Dept Psychiat, Neurochem Res Unit, Edmonton, AB T6G 2G3, Canada

[3] Fac Med, GIS Medicament, F-44035 Nantes, France

来源：

NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS | 1999年 / 23卷 / 04期

基金：

英国医学研究理事会;

关键词：

MDMA; MDA; MDE; Ecstasy; Adam; Love; Eve; recreational drug use; toxicity; psychopathology; neurotoxicity; abuse potential; metabolic interactions;

D O I：

10.1016/S0149-7634(98)00046-3

中图分类号：

B84 [心理学]; C [社会科学总论]; Q98 [人类学];

学科分类号：

03 ; 0303 ; 030303 ; 04 ; 0402 ;

摘要：

The 3,4-methylenedioxy analogues of amphetamine [MDMA ("Ecstasy", "Adam''), MDA ("Love") and MDE ("Eve'')] are recreational drugs that produce feelings of euphoria and energy and a desire to socialize, which go far to explain their current popularity as "rave drugs''. In addition to these positive effects, the drugs are relatively inexpensive to purchase and have the reputation of being safe compared to other recreational drugs. Yet there is mounting evidence that these drugs do not deserve this reputation of being safe. This review examines the relevant human and animal literature to delineate the possible risks MDMA, MDA and MDE engender with oral consumption in humans. Following a summary of the behavioral and cognitive effects of MDMA, MDA and MDE, risks will be discussed in terms of toxicity, psychopathology, neurotoxicity, abuse potential and the potential for drug-drug interactions associated with acute and chronic use. (C) 1999 Elsevier Science Ltd. All rights reserved.

引用

页码：539 / 553

页数：15

共 162 条

[1]

AGHAJANIAN GK, 1990, ANN NY ACAD SCI, V600, P93

[2] ORAL-ADMINISTRATION OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) PRODUCES SELECTIVE SEROTONERGIC DEPLETION IN THE NONHUMAN PRIMATE [J].

ALI, SF ;

NEWPORT, GD ;

SCALLET, AC ;

BINIENDA, Z ;

FERGUSON, SA ;

BAILEY, JR ;

PAULE, MG ;

SLIKKER, W .

NEUROTOXICOLOGY AND TERATOLOGY, 1993, 15 (02) :91-96

[3]

Alles G. A., 1959, NEUROPHARMACOLOGY, P181

[4]

Axt KJ, 1994, AMPHETAMINE ITS ANAL, P315

[5]

BAKER LE, 1995, BEHAV PHARMACOL, V6, P263

[6]

BARRETT PJ, 1993, J ROY SOC MED, V86, P233

[7] MDMA-INDUCED NEUROTOXICITY - PARAMETERS OF DEGENERATION AND RECOVERY OF BRAIN-SEROTONIN NEURONS [J].

BATTAGLIA, G ;

YEH, SY ;

DESOUZA, EB .

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1988, 29 (02) :269-274

[8] SELF-ADMINISTRATION OF METHYLENEDIOXYMETHAMPHETAMINE (MDMA) BY RHESUS-MONKEYS [J].

BEARDSLEY, PM ;

BALSTER, RL ;

HARRIS, LS .

DRUG AND ALCOHOL DEPENDENCE, 1986, 18 (02) :149-157

[9]

BECK J, 1990, ECSTASY CLIN PHARM N, P77

[10] BEHAVIORAL-EFFECTS OF N-ETHYL-3,4-METHYLENEDIOXYAMPHETAMINE (MDE - EVE) [J].

BOJA, JW ;

SCHECHTER, MD .

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1987, 28 (02) :153-156

← 1 2 3 4 5 6 7 8 9 10 →